By Adriano Marchese

AstraZeneca PLC (AZN.LN) said Monday that its drug Brilinta met the primary endpoint in a phase three trial for stroke prevention.

The British pharmaceutical major said high-level results from the phase three THALES trial showed Brilinta used twice daily with aspirin reached a statistically significant reduction in the risk of the primary composite endpoint of stroke and death.

"Results of the Phase three THALES trial showed Brilinta, in combination with aspirin, improved outcomes in patients who had experienced a minor acute ischaemic stroke or high-risk transient ischaemic attack," Executive Vice President of BioPharmaceuticals R&D Mene Pangalos said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

January 27, 2020 02:39 ET (07:39 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca